Mallinckrodt announces publication on H.P. Acthar Gel
Mallinckrodt announced the publication of a company-initiated literature review of clinical and economic data on H.P. Acthar Gel across seven autoimmune and inflammatory disorders - all approved indications for the product. The evidence supported the use of H.P. Acthar Gel across the indications reviewed, pointing to a reduced need for background medications and lower post-therapy healthcare utilization and medical costs. The analysis, which summarizes data from the Academy of Managed Care Pharmacy (AMCP) Formulary dossier for H.P. Acthar Gel was published online in the June 28 issue of Advances in Therapy and titled "Clinical and Economic Evaluation of Repository Corticotropin Injection: A Narrative Literature Review of Treatment Efficacy and Healthcare Resource Utilization for Seven Key Indications."